Leap Therapeutics, Inc. (LPTX)

NASDAQ: LPTX · Real-Time Price · USD
0.3743
+0.0333 (9.77%)
Apr 17, 2025, 4:00 PM EDT - Market closed
9.77%
Market Cap 14.99M
Revenue (ttm) n/a
Net Income (ttm) -68.02M
Shares Out 41.26M
EPS (ttm) -1.81
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 305,646
Open 0.3560
Previous Close 0.3410
Day's Range 0.3522 - 0.3625
52-Week Range 0.2220 - 4.7900
Beta 0.21
Analysts Buy
Price Target 8.00 (+2,037.32%)
Earnings Date May 12, 2025

About LPTX

Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase II clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501. Leap Therapeutics, ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2011
Employees 52
Stock Exchange NASDAQ
Ticker Symbol LPTX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 2 analysts, the average rating for LPTX stock is "Buy." The 12-month stock price forecast is $8.0, which is an increase of 2,037.32% from the latest price.

Price Target
$8.0
(2,037.32% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Leap Therapeutics to Host Virtual KOL Event to Discuss Sirexatamab (DKN-01) in Second-line Patients with Advanced Microsatellite Stable Colorectal Cancer

Virtual KOL Event on Wednesday, April 23, 2025, at 2:30 p.m. ET CAMBRIDGE, Mass.

3 days ago - PRNewsWire

Leap Therapeutics (LPTX) Conference Call to discuss Updated Data from Part B of the DeFianCe Study Transcript

Leap Therapeutics (NASDAQ:LPTX) Conference Call to discuss Updated Data from Part B of the DeFianCe Study March 26, 2025 8:00 AM ET Company Participants Douglas Onsi - President and CEO Cyndi Sirard ...

18 days ago - Seeking Alpha

Penny Stock Leap Therapeutics Unveils Positive Data From Experimental Combo Therapy For Colorectal Cancer

Leap Therapeutics, Inc.  LPTX presented updated preliminary data on Wednesday from Part B of the DeFianCe Phase 2 trial of sirexatamab (DKN-01) in combination with bevacizumab and chemotherapy (Experi...

23 days ago - Benzinga

Leap Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results

Leap to host a conference call to present updated CRC clinical data today, March 26, 2025, at 8:00 a.m. ET CAMBRIDGE, Mass.

23 days ago - PRNewsWire

Leap Therapeutics Reports Positive Updated Data from Sirexatamab Colorectal Cancer Study

Updated data confirms statistically significant 32% higher ORR and 3.5 month longer PFS  in second-line CRC patients with high DKK1 levels treated with sirexatamab plus bevacizumab and chemotherapy St...

23 days ago - PRNewsWire

Leap Therapeutics Reports Initial Clinical Data from Part B of the DeFianCe Study and Part C of the DisTinGuish Study

35% objective response rate (ORR) in second-line colorectal cancer (CRC) patients treated with sirexatamab (DKN-01) plus bevacizumab and chemotherapy, compared to 23% ORR in the control arm DKK1 level...

2 months ago - PRNewsWire

Leap Therapeutics: A Buy On Near-Term Data Catalysts In Stomach And Colon Cancer

Leap Therapeutics focuses on developing DKN-01, a promising monoclonal antibody for solid tumors, with encouraging early trial data in GI cancers. LPTX has a short operational runway with less than a ...

3 months ago - Seeking Alpha

Leap Therapeutics to Participate at the 43rd Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass. , Jan. 6, 2025 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that Dou...

3 months ago - PRNewsWire

Leap Therapeutics to Participate at Piper Sandler 36th Annual Healthcare Conference

CAMBRIDGE, Mass. , Nov. 26, 2024 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that Do...

5 months ago - PRNewsWire

Leap Therapeutics Reports Third Quarter 2024 Financial Results

CAMBRIDGE, Mass. , Nov. 13, 2024 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financia...

5 months ago - PRNewsWire

Leap Therapeutics Announces Completion of Enrollment in Part B of the DeFianCe Study of DKN-01 for the Treatment of Colorectal Cancer Patients

CAMBRIDGE, Mass. , Sept. 30, 2024 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that ...

7 months ago - PRNewsWire

Leap Therapeutics Reports Second Quarter 2024 Financial Results

CAMBRIDGE, Mass. , Aug. 12, 2024  /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financi...

8 months ago - PRNewsWire

Leap Therapeutics Reports First Quarter 2024 Financial Results

CAMBRIDGE, Mass. , May 13, 2024 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial...

1 year ago - PRNewsWire

Leap Therapeutics Announces $40 Million Private Placement

Net proceeds, along with existing cash, cash equivalents, and marketable securities are expected to extend cash runway into Q2 2026 and enable expansion of DKN-01 DeFianCe clinical trial and developme...

1 year ago - PRNewsWire

Leap Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results

CAMBRIDGE, Mass. , March 18, 2024 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financi...

1 year ago - PRNewsWire

Leap Therapeutics to Present New Clinical Data from Part A of DeFianCe Study at the 2024 ASCO Gastrointestinal Cancers Symposium

30% ORR and 93% DCR across heterogenous second-line CRC patients treated with DKN-01 plus bevacizumab and chemotherapy Subgroup analysis reveals greatest benefit in left-sided tumors, particularly rec...

1 year ago - PRNewsWire

Leap Therapeutics to Participate at the 42nd Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass. , Jan. 3, 2024 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that Dou...

1 year ago - PRNewsWire

Leap Therapeutics Announces Completion of Enrollment in Randomized Controlled Part C of the DisTinGuish Study of DKN-01 for the Treatment of Gastric Cancer Patients

CAMBRIDGE, Mass. , Jan. 2, 2024 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that enr...

1 year ago - PRNewsWire

Leap Therapeutics to Present New Data from Part A of the DeFianCe Study of DKN-01 Plus Bevacizumab and Chemotherapy in Colorectal Cancer Patients at the 2024 ASCO Gastrointestinal Cancers Symposium

CAMBRIDGE, Mass. , Dec. 11, 2023 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that th...

1 year ago - PRNewsWire

Leap Therapeutics to Participate at Piper Sandler 35th Annual Healthcare Conference

CAMBRIDGE, Mass. , Nov. 21, 2023 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that Do...

1 year ago - PRNewsWire

Leap Therapeutics Reports Third Quarter 2023 Financial Results

CAMBRIDGE, Mass. , Nov. 13, 2023 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financia...

1 year ago - PRNewsWire

Leap Therapeutics to Participate at Upcoming Investor Conferences

CAMBRIDGE, Mass. , Sept. 5, 2023 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that Do...

1 year ago - PRNewsWire

Leap Therapeutics Reports Second Quarter 2023 Financial Results

CAMBRIDGE, Mass. , Aug, 14, 2023 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financia...

1 year ago - PRNewsWire

Leap Therapeutics Announces Initiation of Randomized Controlled Part B of the DeFianCe Study of DKN-01 in Colorectal Cancer Patients

CAMBRIDGE, Mass., July 12, 2023 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that, ba...

1 year ago - PRNewsWire

Leap Therapeutics Announces Reverse Stock Split

CAMBRIDGE, Mass. , June 20, 2023 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that it...

1 year ago - PRNewsWire